Chr rearrangement(11)(q23)
|
AML
|
Chr rearrangement(11)(q23)
|
AML
|
cytarabine/daunorubicin liposomal formulation Resistant: C3 – Early Trials
|
cytarabine / daunorubicin liposomal formulation Resistant: C3 – Early Trials
|
Chr rearrangement(11)(q23)
|
AML
|
Chr rearrangement(11)(q23)
|
AML
|
cytarabine Resistant: C3 – Early Trials
|
cytarabine Resistant: C3 – Early Trials
|